이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

난소 조직 동종 이식

2026년 11월 12일 업데이트: University Hospitals Cleveland Medical Center

면역억제를 사용하여 유전적으로 동일하지 않은 형제자매 간의 원발성 난소 부전 상황에서 난소 조직 동종 이식

Premature ovarian failure, also known as primary ovarian insufficiency (POI), or premature menopause, affects 1-2% of women under 40. The diagnosis is typically made based on high levels of follicle stimulating hormone (FSH) and absent or irregular menstrual periods. It leads to infertility and menopause-like effects (hot flashes and thin bones) due to low estrogen levels. POI can result from various factors such as genetic conditions, autoimmune diseases, or previous medical treatments like chemotherapy.

Treatment of POI usually involves hormone replacement therapy and, if pregnancy is desired, assisted reproductive technologies such as in vitro fertilization (IVF) using an egg donor. However, IVF may not be an option for everyone due to personal, religious, ethical or financial reasons. Recent advances in medicine have identified ovarian tissue transplantation (OTT) as a potential solution. OTT involves transplanting either fresh or frozen ovarian tissue into the pelvic area, where it can begin functioning again. Studies in animals and humans have shown success in restoring hormonal function and even achieving pregnancies in some cases. Initial human trials of ovarian tissue transplants from another individual began with identical twins and have since expanded to include non-identical siblings with compatible tissue matches using immunosuppression. Success rates of OTT have been promising, with multiple live births reported between identical twins. Long-term studies indicate that transplanted tissue can remain functional for up to eight years. Ovarian tissue transplantation offers a promising avenue for women with POI to help restore fertility and hormonal function. Continued research and refinement of tissue techniques are essential to improve outcomes and expand access to this innovative treatment option.

This study will enroll 10 participants who will undergo ovarian tissue transplantation donated by a non-identical sister using an immunosuppression protocol at University Hospitals.

연구 개요

연구 유형

중재적

등록 (추정된)

10

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Ohio
      • Cleveland, Ohio, 미국, 44106

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

21년 (성인)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

여성

설명

Inclusion Criteria (Donor):

  • Must meet criteria for ovarian sufficiency: Menstruating; Premenopausal serum hormone (FSH, LH, estradiol, AMH) levels
  • Must be between the ages of 21-35 years old.
  • Must be genetic sister to recipient participant, which will be assessed by patient report.
  • Must have history of at least one healthy live birth.
  • Must have more than one ovary (i.e. must have both the left and right ovary).
  • Must be willing to undergo a donor transplant evaluation including serologies and nucleic acid testing (NAT, which is essentially rapid PCR) for infectious conditions.
  • Must have normal female karyotype (46,XX).
  • Must have negative testing for HIV type 1 and 2, Hepatitis B, Hepatitis C, syphilis, West Nile Virus, gonorrhea and chlamydia.
  • Must be willing to undergo general anesthesia, minimally invasive gynecologic surgery, and loss of unilateral ovary.
  • If patient is a smoker, 3 months cessation is required prior to enrollment and must pass a nicotine test.
  • Must be willing and able to sign informed consent and follow all outlined procedures and recommendations in the protocol.
  • Donors (with their marital partners, when applicable) must be willing to seek independent legal advice from attorneys with specific expertise in third-party reproduction to determine their legal rights and duties in entering into a donor reproductive tissue arrangements.

Inclusion Criteria (Recipient):

  • Must meet criteria for primary ovarian insufficiency: Amenorrheic x12 months; Serum hormone (FSH, LH, estradiol, AMH) levels consistent with menopause
  • Must be between the ages of 21-40 years old.
  • Must be in a committed relationship with a male partner.
  • Must be willing to attempt natural conception within 4 months following transplant.
  • Must be willing to undergo a pre-transplant evaluation.
  • Must be willing to undergo Maternal Fetal Medicine consultation and evaluation for safety of pregnancy, particularly patients at risk of complications in pregnancy (e.g. Turner syndrome patients).
  • Must be willing to undergo general anesthesia, minimally invasive gynecologic surgery, pregnancy with potential high risk complications, and surgery to remove the graft
  • Must be willing and able to receive potent immunosuppressive medications and must be able to follow standard infection prophylaxis protocols
  • Must have been offered and declined donor oocyte IVF as a first line treatment option
  • Must be willing to receive standard vaccinations such as influenza, Hepatitis B. If age and circumstances indicate, be willing to receive vaccines against pneumococcus, HPV and Hepatitis A.
  • If patient is a smoker, 3 months cessation is required prior to enrollment and must pass a nicotine test.
  • Must be willing and able to sign informed consent and follow all outlined procedures and recommendations in the protocol, including assent for monitoring neonatal outcomes for the first year after birth.
  • Intended parents (meaning, the recipient and partner) must be willing to seek independent legal advice from attorneys with specific expertise in third-party reproduction to determine their legal rights and duties in entering into a donor reproductive tissue arrangements.

Inclusion Criteria (Recipient Male Partner)

  • Must be age 18 years or older (and a combined age not greater than 110 years).
  • Must have a normal semen analysis.
  • Must be willing and able to sign informed consent.
  • Intended parents (meaning, the recipient and partner) must be willing to seek independent legal advice from attorneys with specific expertise in third-party reproduction to determine their legal rights and duties in entering into a donor reproductive tissue arrangements.

Exclusion Criteria (Donor) (to be verified by history and review of the medical chart by the study team)

  • History of hypertension, diabetes, or significant heart, liver, kidney or central nervous system disease.
  • Any medical diagnosis placing the subject at high risk of surgical complications based on the team's review of medical history.
  • Current smoker (smoking cessation must have occurred 3 months prior to enrollment).
  • History of prior malignancy except for cervical cancer in stage 1a or 1b after 3 years.
  • History of human immunodeficiency virus (HIV), mycobacteria, hepatitis C.
  • Hepatitis B infection (Hepatitis B risk is for those with HepB surface antigen and/or HBV DNA positive. Those that are HepB core antibody true-positive are at minimal risk of reactivation. Those with vaccine-induced HepB surface antibody are not at risk).
  • Presence of active documented systemic infection or recent systemic infection within the past three months: Positive for syphilis (T. pallidum), chlamydia (C. trachomatis) or gonorrhea (N. gonorrhea).
  • BMI greater than 35 kg/m2

Exclusion Criteria (Recipient)

  • History of hypertension, diabetes, or significant heart, liver, kidney or central nervous system disease. Serum creatinine level >1.0 mg/dL.
  • Any medical diagnosis placing the subject at high risk of surgical complications based on the team's review of medical history.
  • Current smoker (smoking cessation must have occurred 3 months prior to enrollment).
  • Active HPV infection.
  • History of prior malignancy except for cervical cancer in stage 1a or 1b after 3 years.
  • History of human immunodeficiency virus (HIV), mycobacteria, hepatitis C.
  • Hepatitis B infection (Hepatitis B risk is for those with HepB surface antigen and/or HBV DNA positive. Those that are HepB core antibody true-positive are at minimal risk of reactivation. Those with vaccine-induced HepB surface antibody are not at risk).
  • Presence of active documented systemic infection or recent systemic infection within the past three months.
  • Significant mental illness or substance abuse.
  • BMI greater than 30 kg/m2
  • Prior organ transplant with rejection, infection, or graft thrombosis.

Exclusion Criteria (Recipient Male Partner )

  • Inability to complete regular intercourse.
  • History of incarceration.
  • Significant mental illness or substance abuse.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Ovarian tissue recipient

Any recipient that receives ovarian tissue transplantation

Participants will receive donor ovarian tissue with immunosuppression

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
환자 보고서에 따라 측정된 이식 후 월경 재개까지의 시간(일)
기간: 최대 6개월
최대 6개월
의료 기록 보고서/환자 보고서로 측정된 정상 출산 수
기간: 최대 3년
최대 3년

2차 결과 측정

결과 측정
기간
의료 기록/환자 보고서에 의해 측정된 이식부터 임신까지의 시간(일)
기간: 최대 2년
최대 2년

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Rebecca Flyckt, MD, University Hospitals Cleveland Medical Center
  • 수석 연구원: Kathryn Coyne, MD, University Hospitals Cleveland Medical Center

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2027년 2월 1일

기본 완료 (추정된)

2030년 5월 30일

연구 완료 (추정된)

2030년 5월 30일

연구 등록 날짜

최초 제출

2024년 11월 1일

QC 기준을 충족하는 최초 제출

2024년 11월 1일

처음 게시됨 (실제)

2024년 11월 4일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 17일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 12일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다